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Abstract
Objective: The measurement of plasma glycated albumin is particularly useful in the short-middle term monitoring of glycometabolic control
in diabetics. The aim of this work is to evaluate a new enzymatic method for the measurement of glycated albumin in plasma, with particular
attention to some selected cases and comparison with other relevant tests (fasting plasma glucose, after glucose load, fructosamine, glycated
hemoglobin).
Design and methods: We have performed a multicenter study by which sample collection was performed in three different centers (Milano,
Padova and Cagliari) and serum samples, frozen at −80 °C, were then delivered under dry ice to the centralized laboratory in Milano. Glycated
plasma albumin was measured with reagents from Asahi Kasei Pharma (Lucica GA-L enzymatic assay; AKP, Tokyo, Japan) on a Modular P
Roche system. Fructosamine was assessed by a Roche method and HbA1c (measured separately in the three centers on fresh EDTA blood) by
DCCT-aligned HPLC systems. We have investigated 50 type 2 diabetics, 26 subjects with gestational diabetes, 35 subjects with thalassemia major,
10 subjects with cirrhosis, 23 patients with end-stage renal disease subjected to dialysis treatment and 32 healthy adult control subjects.
Results: The main analytical performance characteristics of the new GA test were the following: (a) the within-assay reproducibility was
between 3.0 and 3.9% (in terms of GA% CV, measured on 2 serum pools and 2 control materials at normal and pathological glycated albumin
levels); (b) the between-assays reproducibility was from 2.8 to 4.1%; (c) the linearity was tested in the interval between 13 and 36% and found
acceptable (r2=0.9932). Concerning the clinical utility of the new test, we have evaluated the relationships between GA, HbA1c, fructosamine and
fasting and post-prandial glucose in several patients, as well as the changes in the abovementioned parameters in a sub-group of type 2 diabetic
patients for 18 weeks as they progressed from severe hyperglycemia (HbA1c ≥10.0%) toward a better glycemic control. The correlations between
glycated albumin and HbA1c were as follows: (a) type 2 diabetics: r
2=0.483 (good glycemic control), r2=0.577 (poor control); (b) diabetic
patients under dialysis: r2=0.480; (c) liver disease: r2=0.186; (d) transfused non-diabetics with thalassemia: r2=0.004. Glycated albumin, as well
as HbA1c and fructosamine, was of little value in the study of women with gestational diabetes, mainly because of the very limited glucose
fluctuations in this particular category of subjects. In 11 type 2 diabetic patients under poor metabolic control, GA was better correlated with
fasting plasma glucose then HbA1c (r
2=0.555 vs. 0.291, respectively), and decreased more rapidly than HbA1c during intensive insulin therapy.Abbreviation: GA, glycated albumin
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1399R. Paroni et al. / Clinical Biochemistry 40 (2007) 1398–1405Conclusions: The experience we have acquired with the new enzymatic test demonstrates its reproducibility and robustness. We confirm that
plasma glycated albumin is better related to fasting plasma glucose with respect to HbA1c. Moreover, glycated albumin is more sensitive than
HbA1c with regard to short-term variations of glycemic control during treatment of diabetic patients. This test is also very appropriate when the
interpretation of HbA1c is critical.
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Glucose in humans is able to bind to several proteins, such as
hemoglobin, collagen, immunoglobulins and others, thus
producing non-enzymatic adducts in the form of ketoamine
and other compounds [1,2]. In diabetic patients, because of
chronic hyperglycemia, such compounds may have a direct link
to the development of glucose-related complications, as clearly
proven by some important clinical trials, such as the DCCT and
UKPDS [3,4]. In the case of hemoglobin, the measurement of
glycated hemoglobin in blood is very useful to estimate the
average mean blood glucose over the previous 2 months [5],
and is now also indicated for estimating the risk of developing
macrovascular complications in non-diabetic subjects [6].
The measurement of glycated albumin (GA) in serum has not
gained the same popularity as glycated hemoglobin, partly
because of the lack of specificity or poor standardization of the
proposed methods, and partly because the main clinical trials
dedicated to defining the relationship between hyperglycemia
and diabetic complications have been designed with attention
focussed to glycated hemoglobin. Indeed, the concentration of
GA in serum can be measured, as in the case of glycated
hemoglobin, on the basis of different principles, such as affinity
chromatography [7,8], ion exchange liquid chromatography
[9,10], colorimetry [11,12] and immunochemistry [13,14].
However, all these methods suffer from a number of disadvan-
tages, namely, poor precision and long processing times.
In the last years, a novel three-step enzymatic procedure to
determine GA has been developed. The new procedure com-
prises: (a) the assay of GA concentration using an albumin-
specific proteinase and ketoamine oxidase; (b) the measure of
total albumin concentration by bromocresol green and (c) the
calculation of GA percentage in total albumin [15]. Later on,
such a method was improved by adding a step to remove the
glycated amino acids and substituting bromocresol green with
bromocresol purple in order to increase specificity in the
measurement of total albumin [16]. Moreover, recently, a dry
chemistry system (GA monitor) via this same enzymatic
method was proposed in order to provide a GA value
measurement for point of care testing (POCT) [17].
In this investigation, we report our experience with this new
assay for measuring GA in serum, which has been evaluated for
its analytical performance and clinical utility. To this regard, we
have studied several diabetic patients under different conditions,
including those suffering from nephropathy and thalassemia
major, whose interpretation of glycated hemoglobin is particu-
larly difficult because of repeated red cell transfusions. A
comparison with fasting and non-fasting plasma glucose,glycated hemoglobin and serum fructosamine has also been
performed to highlight the potential advantages and limitations
of the proposed new test.
Materials and methods
Patients
Patients were enrolled in three different centers: University
of Padova, University of Cagliari and S. Raffaele Hospital in
Milano. Eight groups of patients were enrolled, and selected as
follows. Group 1: type 2 diabetic patients in good metabolic
control (n=40; 23 men, 17 women; mean age [±SD] 62±7
years; mean disease duration 7±8 years; all treated with diet and
hypoglycemic drugs); group 2: type 2 diabetic patients in poor
metabolic control (n=11; 5 men, 6 women; age 59±9 years;
mean disease duration 8±8 years; all treated with insulin);
group 3: patients with end-stage renal disease subjected to
dialysis treatment without diabetes (n=16; 12 men and 4
women, age 71±9 years) and with diabetes (n=7; 4 men and 3
women, age 68±11 years); group 4: women with gestational
diabetes mellitus (GDM) (n=26; age 35±4 years; 21 treated
with diet, 5 with diet and insulin); group 5: thalassemic
(Cooley's disease) non-diabetic patients (n=19; 11 men and 8
women, age 25±6 years); group 6: thalassemic (Cooley's
disease) patients with diabetes (n=15; 8 men and 7 women, age
28±3 years); group 7: patients with cirrhosis (n=10; 4 men and
6 women, age 52±8 years); group 8: normal control subjects
(blood donors; n=32; 12 men and 20 women, age 41±
10 years). Exclusion criteria for the patients with liver disease
were the presence of diabetes mellitus. Group 2 patients were
monitored at baseline and every 2 weeks for about 2 months,
while group 4 patients were monitored every 2 weeks until
delivery.
All patients gave informed consent to the study that was
approved by the local Ethical Commission.
Laboratory measurements
EDTA-plasma samples were collected for measuring fasting
glucose, GA and fructosamine. In group 1, 2 and 4, samples for
post-prandial (1 hr after lunch) plasma glucose were also
collected. Glucose measurements were performed directly in the
three centers by enzymatic methods [18]. The remaining plasma
aliquots were immediately frozen, stored at −80 °C and sent
within 3 months to the centralized laboratory in Milano for GA
and fructosamine quantification. A Roche Modular–P system
automatic clinical analyzer (Roche, Milano) was used for
Table 2
Between-run imprecision
Parameter Control Pool
Level 1
(n=6)
Level 2
(n=6)
Level 1
(n=11)
Level 2
(n=10)
Albumin (g/dL)
Mean (SD) 4.57 (0.15) 4.53 (0.11) 4.33 (0.07) 3.64 (0.10)
CV (%) 3.3 2.8 1.7 2.8
Glycated albumin
(g/dL)
Mean (SD) 0.59 (0.02) 1.79 (0.06) 0.57 (0.02) 0.85 (0.04)
CV (%) 2.7 3.6 4.4 4.5
Glycated albumin
(%)
Mean (SD) 14.3 (0.42) 37.5 (1.1) 14.6 (0.56) 23.5 (0.97)
CV (%) 2.8 3.0 3.9 4.1
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Kasei Pharma Corp., Tokyo, Japan), and fructosamine by Roche
reagents [19]. A separate set of EDTA-blood samples was
collected, stored and shipped in the same condition for
measuring the HbA1c concentrations to the same centralized
laboratory in Milano. HbA1c was measured by HPLC using an
automated system (Bio-Rad Variant II dual kit, Bio-Rad
Laboratories, Segrate, Milano) aligned to the DCCT method,
as previously described [18].
Analytical evaluation of Lucica® GA-L enzymatic assay
Analytical imprecision was evaluated using different speci-
mens. Within-run reproducibility was estimated using two
control materials with normal (Level 1) or raised (Level 2)
values of GA, and two plasma pool samples with normal (Level
1) and abnormal (Level 2) concentrations of GA with 9–11
replicates. The control materials with normal and raised GA
levels were liophylized human sera obtained from the
Manufacturer (BML Inc., Tokyo, Japan). In 1 day, we performed
two runs. The same specimens were used for evaluating the
between-run imprecision with 6 (controls) and 10–11 (pools)
independent runs over 7 months. The controls analyzed for
between-run imprecision were only 6 because we had to change
a lot of controls during the period of test evaluation.
Linearity was assessed by assaying 11 samples prepared by
mixing different volumes of a low-level serum pool (approxi-
mately 13% GA) and a high level serum pool (approximately
35% GA) to obtain various GA values between these limits.
Each specimen was measured in duplicate and the means of the
GA percentage were plotted on the on y-axis vs. dilution on the
x-axis.
Interference due to lipids, bilirubin and hemoglobin was
evaluated by analyzing aliquots from a normal sera pool to
which known amounts of a lipid emulsion (Intralipid,
Pharmacia, Milan, Italy; 1.13–13.5 mmol/L final concentra-
tion), bilirubin (Sigma, Milan, Italy; 7.7–1290 μmol/L final
concentration) and hemoglobin (0.25–2.5 g/L) were added
separately. Interference was assumed to be significant when bias
resulted to exceed ±10% with respect to the basal (i.e. without
interference) level.Table 1
Within-run imprecision
Parameter Control Pool
Level 1
(n=9)
Level 2
(n=9)
Level 1
(n=11)
Level 2
(n=10)
Albumin (g/dL)
Mean (SD) 4.49 (0.17) 4.49 (0.10) 4.33 (0.07) 3.65 (0.10)
CV (%) 3.8 2.2 1.6 2.7
Glycated albumin
(g/dL)
Mean (SD) 0.58 (0.02) 1.77 (0.07) 0.57 (0.02) 0.86 (0.04)
CV (%) 3.9 4.2 4.2 4.2
Glycated albumin
(%)
Mean (SD) 14.3 (0.42) 37.4 (1.2) 14.6 (0.54) 23.5 (0.92)
CV (%) 3.0 3.2 3.7 3.9Statistical analysis
Values were expressed as mean±SD, CVs or median (2.5th-
97.5th percentiles) when not normally distributed. In order to
assess the significance of the differences the Mann–Whitney
Rank Sum Test was used. Linear regression analysis was
performed by the least squares method. All statistical analyses
were performed using SigmaStat software (Jandel Scientific,
version 3.0).
Results
Analytical imprecision
The results of the reproducibility study for GA measure-
ments are shown in Tables 1 and 2. Within-run and between-run
CVs for GA% in the 4 tested materials were below 3.9% and
4.1%, respectively, the higher values being both found for the
pathological pool. It is worth noting that the expression of GA
as a ratio to total albumin (i.e. GA%) has generally a greater
precision than that of GA expressed in terms of mass
concentration.
Linearity and interferences
The Lucica® GA-L enzymatic assay showed an excellent
linearity in all of the concentration ranges tested. In Fig. 1A, the
mean values of 2 GA determinations are plotted against
dilution. Bilirubin was not found to interfere in the analyses
up to 342 μmol/L with a negative interference (−40%) at
1290 μmol/L (Fig. 1B). Turbidity interference was tested up to
13.5 mmol/L triglycerides, evidencing at this level a positive
bias up to +80%. At 3.9 mmol/L, a bias of +26.2% was found
(Fig. 1C). Hemolysis was tested up to 2.5 g/L, showing a
significant negative bias above 1.75 g/L and about 30%
underestimation at 2.5 g/L (Fig. 1D).
Clinical utility of the GA test
Levels of GA, HbA1c, fructosamine and fasting glucose in all
the categories of subjects studied are summarized in Table 3. In
Fig. 1. Performance characteristics of the glycated albumin enzymatic assay. (A) Linearity in the range of 10–40%. In the insert, the linearity of glycated albumin
expressed in terms of g/dL is reported. (B) Bilirubin interference. (C) Triglycerides interference. (D) Hemoglobin interference. The dashed lines in panels B, C and D
highlight the bias limits of ±10%.
1401R. Paroni et al. / Clinical Biochemistry 40 (2007) 1398–1405almost all the subject categories, the four parameters tested were
significantly higher when compared to control subjects, and this
was particularly evident in type 2 diabetic patients in poor
metabolic control, renal patients and in the thalassemic diabetic
patients.
Comparisons of GAwith HbA1c and fructosamine, and their
relationships of each other with plasma glucose were evaluated.
The most significant findings of these analyses are reported in
Figs. 2 and 3.
In Fig. 2, the results obtained in healthy blood donors and
type 2 diabetic patients in good metabolic control are reported.
These two categories of subjects were pooled in order to coverTable 3
Glycated albumin, HbA1c, fructosamine and fasting glucose among the various grou
Parameter Type 2 diabetes Renal
disease
GDM
Good control Poor control
GA (%) 17.4* 26.4* 15.6* 14.5
14.2–270
(n=39)
22.6–49.9
(n=10)
12.8–35.8
(n=23)
12.3
(n=
HbA1c (%) 6.8* 11.1* 5.9* 5,4
5.9–8.3
(n=39)
9.4–13.1
(n=9)
4.9–9.4
(n=13)*
4.9–
(n=
Fructosamine
(μmol/L)
254* 408* 315* 194
193–315
(n=35)
346–653
(n=10)
260–430
(n=23)
167–
(n=
Fasting glucose
(mmol/L)
7.72* 13.6* 13.8* 4.83
6.33–11.9
(n=39)
8.6–24.0
(n=9)
5.05–15.5
(n=23)
4.22
(n=
Values are reported as median (2.5th–97.5th percentile). *Pb0.01 vs. controls by Mmost of the physiopathological range of the measured para-
meters. In these subjects, positive significant correlations were
found between GA, HbA1c, fructosamine and fasting plasma
glucose (Figs. 2A–C), with the strongest correlation obtained
for HbA1c (r
2 =0.746) (Fig. 2B) which appeared to be better
correlated to fasting glucose with respect to GA (r2 =0.504)
(Fig. 2A). Furthermore, positive correlations, even if weaker,
were found between GA, HbA1c, fructosamine and post-
prandial plasma glucose (Figs. 2A–C). GA and fructosamine
also resulted well correlated (r2 =0.778) (Fig. 2E). Finally, it is
interesting to note that the correlation between GA and HbA1c
(r2 =0.483) (Fig. 2D) is weaker than that of both GA andps of patients
Cooley's Cirrhosis Controls
Non-diabetes Diabetes
11.7* 18.3* 14.1 13.4
–16.5
22)
10.3–13.6
(n=19)
11.0–41.2
(n=14)
11.7–15.9
(n=10)
11.7–16.9
(n=32)
6.6* 8.2* 5.4 5.3
6.9
22)
6.0–8.2
(n=19)
6.1–13.5
(n=15)
4.7–5.9
(n=10)
4.7–5.7
(n=32)
200 271* 228* 192
216
21)
175–223
(n=19)
180–569
(n=14)
180–255
(n=10)
149–242
(n=22)
5.22* 8.55* 5.27* 4.66
–6.72
22)
4.72–5.88
(n=19)
4.77–18.26
(n=15)
4.33–6.61
(n=10)
4.05–5.44
(n=32)
ann–Withney Rank Sum Test.
Fig. 2. Scatter plots of glycated albumin (A), HbA1c (B) and fructosamine (C) vs. fasting plasma glucose in healthy blood donors and type 2 diabetic patients with good
metabolic control. Relationships between glycated albumin and HbA1c (D) and between glycated albumin and fructosamine (E) are reported in the lower part of the
figure. Dashed lines in the regression plots represent 95% regression confidence intervals.
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2 =0.504 and r2 =0.746,
respectively) (Figs. 2A and B). It is also to be noted that
apparently at very low glucose concentrations, a minimum of
GA and HbA1c could be still expected (as evident from the
intercepts of the regression lines of Figs. 2A and B), but that no
GA could be expected if HbA1c would be absent and viceFig. 3. Same parameters and analyses as in Fig. 2, related toversa, as shown by Fig. 2D. The same kind of observations
have been drawn when comparing fructosamine to plasma
glucose (Figs. 2C and E).
The results obtained by analysing the same relationships in
type 2 diabetic patients under poor metabolic control are
reported in Fig. 3. In these patients indeed the relationshipspatients with type 2 diabetes in poor metabolic control.
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post-prandial) or with each other (Figs. 3A, C and E) are
essentially similar to those found in the subjects previously
discussed as evidenced comparing the plots of Figs. 3A, C and
E with those of Figs. 2A, C and E. However, the relationships
between HbA1c and fasting and post-prandial plasma glucose
(r2 =0.291 and r2 =0.228, respectively) (Fig. 3B), and between
HbA1c and GA (r
2 =0.557) (Fig. 3D), looked different, as
clearly evident when comparing Figs. 3B and D with Figs. 2B
and D, respectively. Indeed, the correlation between HbA1c and
fasting plasma glucose was much weaker in type 2 diabetic
patients poorly controlled, with respect to healthy subjects and
type 2 diabetic patients under stable glycometabolic control
(r2 =0.291 vs. 0.746, respectively) (Figs. 3B and 2B).
The evaluation of glycometabolic control based on the
measurement of glycated proteins in subjects having reduced
red cell survival, such as in the case of patients subjected to
regular blood transfusions, in patients with end-stage renal
disease or in women with gestational diabetes, was also
analyzed in our study. In patients with Cooley's disease, we
found that GA is better related to fasting glucose with respect to
HbA1c (r
2 =0.693 vs. 0.370) and that fructosamine and GA are
strictly related to each other (r2 =0.969). A weaker relationship
between GA and fructosamine was also found in patients with
cirrhosis (r2 =0.651). On the contrary, in subjects under regular
dialysis regimen for end-stage renal disease, the correlation
between GA and fructosamine with fasting glucose was much
weaker than in the other categories of subjects (r2 =0.002 and
0.010, with respect to values between 0.5 and 0.6), while the
correlation between HbA1c and fasting glucose was found to be
stronger than in the case of type 2 diabetic patients under poor
metabolic control (r2 =0.420 vs. 0.291). These were the results
we obtained by pooling together the non-diabetic and the
diabetic patients under constant regimen of hemodialysis.
However, the analysis performed only in the diabetic patients
under hemodialysis proved a stronger relationship between GA
and fasting plasma glucose than between HbA1c and fasting
plasma glucose (r2 =0.712 vs. 0.125). In these patients, the
relationship between GA and HbA1c was weaker than in the
diabetic non-hemodialyzed subjects (r2 =0.480 vs. 0.580).
Finally, in the case of women with GDM, all the correlationsFig. 4. Changes in fasting and post-prandial glucose (open and closed circles,
respectively), glycated albumin, (-■-), HbA1c (-▴-) and fructosamine (-★-) in
10 type 2 diabetic patients under poor metabolic control monitored at baseline
(day 0) and every 2 weeks for about 2 months.between GA, HbA1c and fructosamine with fasting or post-
prandial glucose were found to be very weak (r2 always b0.1).
In order to compare the timeline of the changes in the
investigated metabolic indices after the start of therapy, we
compared the results obtained on 10 type 2 diabetic patients
under poor metabolic control and plotted these data in Fig. 4. In
this graph, the time-course of fasting and non-fasting glucose is
plotted together with the time-course of the other metabolic
indices monitored every 2 weeks in seven consecutive visits.
Both GA and fructosamine were found to be strictly related to
the fast metabolic changes that occurred in the first weeks of
therapy.
Discussion
In this investigation, we have evaluated the performance
characteristics of the improved version of Lucica® GA-L assay,
an enzymatic method for the measurement of GA in serum, and
we have tested its utility in a selected cohort of subjects by
comparing its performance with two widely used indices, such
as HbA1c and fructosamine.
Our data indicate a more than acceptable analytical
imprecision, with within- and between-run CVs almost in the
same range and not exceeding the 4.5% limit. We were not able
to understand why the imprecision for total albumin was better
on pools than in controls, while that on glycated albumin (in
terms of g/dL) was found to be more similar among the different
samples. However, despite previously published data [16], we
were able to obtain a better performance with this test. With an
imprecision below 4.1% for GA%, our data are almost in the
same range of the fructosamine test, which has been reported,
with regard to inter-batch imprecision, to be in the 3.6–4.1%
range [19]. Unfortunately, no analytical goals for imprecision of
GA have been defined so far, so there is no target for
comparison. However, with regard to total albumin, the actual
analytical goal for imprecision (CV=1.6% [20]) was found to
be met in one of our specimen (i.e. on the Pool, Level 1 in the
within-run experiment), and slightly higher CVi values were
found in the other specimen in the within- and between-run
imprecision studies. These results can be compared to the
analytical quality of the HbA1c measurements in our labora-
tories, which is in the order of 2.0%, as CV, as previously
reported [18].
With regard to the other analytical characteristics, the
dilution study explored the physiological range up to 35% of
GA, and gave satisfactory results by confirming the good
linearity observed by Kouzuma T. et al. [15] in the 0–100%
range. The limits chosen for testing method linearity (i.e.
between approximately 10 to 35% GA) were decided by
considering that it is quite unusual to find specimens with levels
of glycated albumin N30%, according to the experience of
Kozuma [15]. Indeed, in our experience we have found only 5
subjects over a total of 270 determinations with levels of
glycated albumin slightly greater than 35%.
Our interference study evidenced a −2.8% bias at 264
μmol/L, a −7.5 % at 392 μmol/L and even higher negative
bias for more elevated bilirubin concentrations. This result is
1404 R. Paroni et al. / Clinical Biochemistry 40 (2007) 1398–1405surprising if compared to that of Kouzuma et al. [16] who found
that 279 μmol/L bilirubin did not affect the results of the assay.
We also found that a 3.9 mmol/L triglyceride concentration
(aquite common clinical situation) causes a +26% interference.
These latest data are, however, difficult to compare with those of
Kouzuma et al. [16] who expressed values as turbidity index of
chyle. Concerning hemoglobin concentration, our observations
are in agreement with those of Kouzuma et al. [16] and we found
that hemoglobin affects less strongly the performance of the
assay, and the bias exceeded the −10% limit only above 2.0 g/L.
The concentration limits for testing lipids, bilirubin and
hemoglobin interferences were chosen on the basis of previous
experience in the evaluation of interference in clinical chemistry
instrumentation [21].
Considering that GA reflects the glycometabolic control over
1–2 weeks, in agreement with its half-life of approximately 17
days [22], we decided to evaluate the time changes of GA in
diabetic patients under poor metabolic control, that were started
on insulin therapy in order to achieve in a relatively short time
an acceptable metabolic control. The results we report clearly
show that GA is more useful than HbA1c in detecting early
response to treatment. Therefore, measurement of GA can be
utilized in monitoring patients whose glycemic control is being
improved. Furthermore, in type 2 diabetic patients under poor
metabolic control, the better correlation obtained between GA
and fasting plasma glucose, with respect to that obtained
between HbA1c and fasting plasma glucose, could mean that the
worsening of glycemic control can be better recognized and
monitored with GA rather than with HbA1c.
GA, expressed as GA% and measured by the Lucica-GA
test, was also found to be a robust parameter in patients with
liver cirrhosis. This could be useful in monitoring diabetic pa-
tients with cirrhosis, whose metabolic control is often unstable
and difficult to improve. Indeed, it has been recently reported
that, in 40% of patients with chronic hepatitis, compensated
cirrhosis and patients with chronic hepatitis treated with
ribavirin, HbA1c falls below the non-diabetic reference range
[23].
In patients under constant dialysis regimen, the data on all
the patients we analyzed do not seem to provide evidence that
GA could be better than HbA1c in monitoring glycometabolic
control. However, unfortunately, not in all the patients we have
studied it was possible to obtain HbA1c values in the same
number as for GA and fructosamine. Its is likely that the poorer
relationship we have found between GA and fasting glucose,
with respect to that between HbA1c and fasting plasma glucose,
could be simply an effect of the discrepancy in numbers of
available measurement. Indeed, by analyzing separately the
subgroup of diabetic patients under regular hemodialytic
treatment, we have been able to demonstrate that GA was
better correlated to fasting plasma glucose, with respect to
HbA1c. This finding is in agreement with some recent data
collected from studies on a larger number of patients, where it
was also proven that GA is a better indicator for glycometabolic
control than HbA1c on diabetic patients under hemodialysis
[24]. The possible explanation is that in these patients the
treatment with erythropoietin causes a significant reduction ofred-cell life, and therefore produces lower HbA1c value because
of the increased proportion of young erythrocytes over older
erythrocytes in peripheral blood of those patients.
Our data on gestational diabetes do not seem to indicate that
the measurement of GA provides information particularly
different from that of HbA1c and fructosamine. Indeed in our
experience these pregnant patients are usually under strict
glycemic control, and we found no significative difference in
the glucose levels among patients treated with insulin with
respect to others not treated. Probably GA could be a better
marker for glycometabolic control with respect to HbA1c in case
of pre-gestational diabetes (i.e. in pregnancy of type 1 or type 2
diabetic women) because of larger excursion of glycemic levels
in these subjects, with respect to the GDM pregnancies.
It is interesting to observe that GA, HbA1c and fructosamine
still seem to be affected by a certain level of non-specificity,
since, at very low glucose concentrations, a minimum of GA,
HbA1c and fructosamine could be expected in all our subjects,
as evident from the intercepts on the y-axes of Figs. 2A–C and
Figs. 3A–C. When comparing glycated proteins (Figs. 2D–E
and 3D–E), the relationships were found to be better (i.e. with
no y-intercept), probably because the degree of non-specificity
is similar. We have already pointed out that if HbA1c is
measured by the recently developed IFCC reference method,
the relationship between mean daily blood fasting glucose and
HbA1c is more consistent, since no HbA1c should be expected if
glucose is absent [25].
Concerning the relationship between GA and fructosamine,
our findings indicate that these parameters were more strongly
correlated to each other in 3 of the subjects groups studied
(controls and type 2 diabetic patients under good metabolic
control, type 2 diabetic patients poorly controlled and patients
with Cooley's anemia). This is not surprising since GA and
fructosamine are known to change both in relatively short term
when glycemic control is changing rapidly, due to a shorter half-
life of albumin with respect to hemoglobin. On the contrary, we
found a weaker correlation between GA and fructosamine in
patients with liver disease. It has been proven that fructosamine
exhibited higher values with respect to the actual glycometa-
bolic control [26] because of retardation of protein metabolism
in the presence of chronic liver disease. Since GA is affected by
albumin metabolism, we could expect that GA could also be
elevated in presence of cirrhosis because of the prolongation of
albumin half-life due to reduced albumin synthesis. Indeed
mean fructosamine in cirrhosis cases was higher with respect to
controls, while mean GA was not different between cirrhosis
patients and controls (Table 3). Despite the small number of
subjects with liver cirrhosis investigated (n=10), our data seem
to indicate that in these cases GA and fructosamine behave
differently, GA being more consistent with the degree of
glycemic control respect to fructosamine.
In conclusion, we have provided some preliminary experi-
ences with this enzymatic test for GA, and we can support that
GA% as measured by the Lucica GA-L enzymatic assay is a
useful test in the assessment of glycemic control in different
subjects affected by diabetes mellitus or increased insulin
resistance. The GA enzymatic test proved to be reproducible
1405R. Paroni et al. / Clinical Biochemistry 40 (2007) 1398–1405and robust and was particularly useful in various clinical
situations, especially when HbA1c is difficult to interpret.
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